면역분석법 시장 규모는 2023년에 275억 3,000만 달러로 평가되며, 2024-2031년 CAGR 4.67%로 성장하며, 2031년에는 396억 6,000만 달러에 달할 것으로 예측됩니다. 면역 분석은 특정 항체와의 상호 작용을 분석하여 특정 물질(일반적으로 단백질 및 기타 생체 분자)의 존재와 양을 감지하는 실험 기술입니다. 간단히 말해, 항체는 표적 분자를 인식하고 결합하여 해당 분자를 식별하거나 정량화하는 데 사용됩니다. 면역 분석은 의학, 생물학, 환경 과학, 식품 안전 등 다양한 분야에서 널리 사용되고 있습니다. 의학 분야에서는 일반적으로 감염성 질환 진단, 호르몬 수치 모니터링, 체내 약물 및 독성 물질 식별, 예방 접종에 대한 면역 반응 검사 등에 사용됩니다.
또한 농업에서는 식품의 독소를 확인하기 위해, 환경 모니터링에서는 물과 토양의 오염 물질을 정량화하기 위해 사용됩니다.
이미노 분석 시장을 형성하는 주요 시장 역학
만성질환 증가:
암, 당뇨병, 심혈관 질환과 같은 만성질환의 전 세계 발병률이 증가함에 따라 조기 발견 및 모니터링이 필요하며, 정확하고 신속한 검사를 위해 임상 현장에서 면역 분석에 대한 수요가 증가하고 있습니다.
기술의 진보 :
자동화 및 하이스루풋 시스템 등 면역 분석 기술의 지속적인 발전으로 검사의 효율성, 민감도 및 특이성이 향상되고 있습니다. 이러한 기술 발전은 질병 식별 및 모니터링을 개선하여 면역 분석 시장의 성장을 가속하고 있습니다.
Point-of-care 검사에 대한 수요 증가:
진료소, 재택의료 등 현장에서는 신속하고 신뢰할 수 있는 간편한 진단 검사에 대한 수요가 증가하고 있습니다. 빠른 결과를 얻을 수 있는 면역 분석은 이러한 현장에서 필수적인 툴로 자리 잡으며 시장을 확대하고 있습니다.
의약품 개발 및 치료 분야에서의 용도 확대:
신약 개발, 약동학 및 독성학 연구를 지원하는 면역 분석은 의약품 개발 및 치료에 점점 더 많이 사용되고 있습니다. 이러한 산업에서 R&D에 대한 투자가 증가함에 따라 면역 분석에 대한 수요가 증가하고 있으며, 시장 개척이 가속화되고 있습니다.
주요 과제
고급 면역 분석 시스템의 높은 비용 :
고급 면역 분석 기술의 개발 및 적용에는 많은 비용이 소요됩니다. 이는 고가의 장비와 시약 비용을 포함하며, 중소규모의 검사 시설과 의료 기관이 이러한 기술을 도입하는 데 큰 걸림돌이 되어 시장 확대에 걸림돌이 되고 있습니다.
숙련된 전문가 부족 :
고급 면역 분석법은 첨단 전문 지식을 가진 인력이 조작하고 해석해야 합니다. 교육받은 인력이 부족하여 특히 신흥 지역에서 면역 분석 기술의 효과적인 사용과 수용을 방해하여 시장 확대를 방해하고 있습니다.
주요 동향 :
인공지능(AI)과 머신러닝(ML)의 통합:
인공지능과 머신러닝은 데이터 처리 및 해석을 개선하기 위해 면역 분석 플랫폼에 빠르게 통합되고 있습니다. 이러한 통합은 진단 정확도 향상, 예측 분석, 검사 절차 간소화를 통해 표준 면역 분석 용도의 한계를 뛰어넘을 수 있습니다.
POC(Point-of-Care) 및 재택 검사:
POC(Point-of-Care) 및 가정내 검사를 위해 작고 사용하기 편리한 면역 분석 검사를 설계하는 추세가 증가하고 있습니다. 이러한 전환은 전문 검사 시설의 필요성을 줄이고 즉각적인 결과를 얻을 수 있는 빠르고 편리한 검사 옵션에 대한 수요에 힘입어 이루어지고 있습니다.
다중 분석 :
다수의 분석물을 동시에 검사할 수 있는 다중 분석법이 점점 더 인기를 얻고 있습니다. 이러한 추세는 하나의 검체에서 종합적인 진단 정보를 얻는 동시에 시간과 비용을 절약할 수 있는 높은 처리량과 효율적인 검사 절차에 대한 높은 수요로 인해 인기를 끌고 있습니다.
신흥 시장 진출:
면역 분석 시장은 의료비 지출 증가, 질병 조기 진단에 대한 인식 증가, 의료 인프라 구축 등을 배경으로 신흥 국가에서 확대되고 있습니다. 비용 부담과 규제 장벽 등의 제약이 있지만, 이러한 시장 확대는 면역 분석 기기 제조업체들에게 새로운 가능성을 열어주고 있습니다.
Immunoassay Market size was valued at USD 27.53 Billion in 2023 and is projected to reach USD 39.66 Billion by 2031, growing at a CAGR of 4.67% from 2024 to 2031. An immunoassay is a laboratory technique that detects the presence or quantity of a material, usually a protein or other biomolecule, by analyzing its interaction with certain antibodies. To put it simply, antibodies are used to recognize and bind to the target molecule, allowing it to be identified or quantified. Immunoassays are widely used in a variety of disciplines, including medicine, biology, environmental science, and food safety. In medicine, they are commonly used to diagnose infectious diseases, monitor hormone levels, identify medications or poisons in the body, and test immunological responses to immunizations.
Additionally, they are used in agriculture to identify toxins in food, as well as in environmental monitoring to quantify pollutants in water and soil.
The key market dynamics that are shaping the immunoassay market include:
Increased Prevalence of Chronic Diseases:
The increased global incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders needs early detection and monitoring, is driving the demand for immunoassays in clinical settings for accurate and speedy testing.
Advancements in Technology:
Continuous developments in immunoassay technology, including automation and high-throughput systems, have improved the tests' efficiency, sensitivity and specificity. This technological advancement enables improved illness identification and monitoring, bolstering the expansion of immunoassay market.
Growing Demand for Point-of-Care Testing:
The demand for quick, dependable, and simple diagnostic tests at point-of-care locations (such as clinics and home care) is growing. Immunoassays with quick findings are becoming vital tools in these settings, growing the market.
Expansion of Applications in Drug Development and Therapeutics:
Immunoassays are increasingly used in drug development and therapeutics, where they aid in drug discovery, pharmacokinetics, and toxicology research. The increasing investment in research and development activities in these industries drives up demand for immunoassays, accelerating market expansion.
Key Challenges:
High Cost of Advanced Immunoassay Systems:
The development and application of sophisticated immunoassay technologies are costly. This includes the cost of expensive equipment and reagents, which is a substantial impediment to smaller laboratories and healthcare organizations adopting these technologies, limiting market expansion.
Lack of Skilled Professionals:
Advanced immunoassay findings have to be operated on and interpreted by highly competent individuals. There is a dearth of educated workers, which inhibits the effective usage and acceptance of immunoassay technology, particularly in emerging regions, preventing market expansion.
Key Trends:
Integration of Artificial Intelligence (AI) and Machine Learning (ML):
Artificial intelligence and machine learning are rapidly being integrated into immunoassay platforms to improve data processing and interpretation. This integration enhances diagnosis accuracy, allows for predictive analytics, and streamlines laboratory procedures, extending the limitations of standard immunoassay applications.
Point-of-Care (POC) and Home-Based Testing:
There is a rising trend towards designing compact, user-friendly immunoassay tests for point-of-care and home use. This transition is being driven by the demand for quick, convenient testing choices that yield instant findings, decreasing the need for specialized laboratory facilities.
Multiplex Assays:
Multiplexing, which allows for the simultaneous testing of numerous analytes, is becoming increasingly popular. This trend is gaining popularity owing to high demand for high-throughput, efficient testing procedures that save time and costs while giving comprehensive diagnostic information from a single sample.
Expansion into Emerging Markets:
The immunoassay market is growing in emerging economies, driven by rising healthcare spending, increased awareness of early disease diagnosis, and the creation of healthcare infrastructure. Despite constraints such as cost sensitivity and regulatory hurdles, this expansion opens up new prospects for immunoassay suppliers.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the Immunoassay Market:
North America:
According to Verified Market Research, North America is estimated to dominate during the forecast period. North America, particularly the United States, has an advanced healthcare infrastructure with extensive access to cutting-edge medical technologies. This allows for rapid adoption and integration of immunoassays across a variety of healthcare settings, resulting in market growth.
The region has one of the world's highest healthcare expenditures, with major investments in R&D. This financial capability encourages the use of pricey immunoassay technology in diagnostics and research, hence boosting the market.
Many of the world's leading immunoassay and biotechnology companies are based in North America. These organizations are at the cutting edge of innovation, contributing to the region's market domination through ongoing product development and strategic alliances.
Furthermore, the increased prevalence of chronic diseases in North America needs early detection and monitoring, including cancer, diabetes, and cardiovascular disease. This has resulted in increased demand for immunoassay-based diagnostics, which is driving market expansion in this region.
Asia Pacific:
Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Many Asia Pacific countries are making considerable investments in healthcare infrastructure, such as hospitals and research institutions. This growth enables the use of modern diagnostic technologies, such as immunoassays, to cater to a rising patient base.
This region's economies are growing, thereby, contributing to a rise in healthcare spending. Governments and the corporate sector are increasing their investments in healthcare, especially preventative care and diagnostics, driving up demand for immunoassay technologies.
The public in the Asia Pacific region is becoming more aware of the necessity of early disease identification and frequent health checkups. This trend is resulting in greater use of immunoassays for screening and monitoring a variety of disorders.
Furthermore, chronic disease prevalence is increasing in the Asia Pacific region, with diabetes, cancer, and cardiovascular disease being among the most common. This public health concern emphasizes the importance of efficient and accurate diagnostic tests, such as immunoassays, for effectively managing and controlling these illnesses.
Europe:
Europe's population is ageing, making it increasingly prone to chronic diseases that require regular monitoring and diagnostic tests. As a result, there is a growing demand for immunoassays to identify cardiovascular illnesses, cancer, and autoimmune disorders.
Most European countries have high healthcare standards, with significant public and private investment in healthcare systems. This funding commitment promotes the use of modern diagnostic technologies, such as immunoassays, throughout the region.
Furthermore, Europe is home to some of the world's best research institutes and biotechnology businesses, generating a robust R&D ecosystem. This strong scientific community drives constant innovation in immunoassay technology and the creation of new assays, both of which contribute to market growth.
The Immunoassay Market is segmented based on Product, Technology, Specimen, Application, End-User, And Geography.
Based on Product, the market is segmented into Reagents & Kits and Analyzers. The reagents & kits segment is estimated to dominate the immunoassay market due to their broad use in a range of applications, including clinical diagnostics, research, and drug development. Reagents and kits are required for the execution of immunoassays and are used in greater numbers than analyzers, which are capital equipment with longer replacement cycles. The need for reagents and kits stems from the necessity for regular replenishment, the development of new tests, and the expansion of immunoassay applications in both healthcare and research contexts.
Based on Technology, the immunoassay market is segmented into ELISA, CLIA, IFA, Rapid Tests, ELISpot, Western Blotting and Others. The ELISA segment is estimated to exhibit the highest growth in the market over the forecast period owing to its broad use in clinical and scientific contexts due to its specificity, sensitivity, and adaptability. This technique is well-known and has been well-validated for a variety of applications, including illness diagnosis, vaccine development, and quality control operations. Furthermore, ELISA kits are available for a wide range of targets, making them the preferred method for detecting and measuring proteins, hormones, antibodies, and antigens.
Based on Specimen, the market is segmented into Blood, Saliva, Urine and Other Specimens. The blood specimen segment is estimated to lead this segment during the forecast period. This dominance is attributed to blood tests' rich diagnostic information, which makes them the preferred option for a wide range of disorders and conditions. Blood-based immunoassays are essential for detecting viral diseases, hormone imbalances, drug monitoring, and biomarkers for a variety of chronic and acute illnesses. Blood tests are widely used in clinical diagnostics due to their reliability, accuracy, and broad applicability, as well as standardized collection and processing techniques.
Based on Application, the market is segmented into Infectious Diseases, Endocrinology, Oncology, Bone & Mineral Disorders, Cardiology, Blood Screening, Autoimmune Disorders, Allergy Diagnostics, Toxicology, Newborn Screening and Other Applications. Infectious Disease is estimated to hold the majority share in the immunoassay market owing to the high global prevalence of infectious diseases such as HIV, TB, and hepatitis, as well as the increasing occurrence of new and emerging infections. The COVID-19 pandemic emphasized the importance of immunoassays in detecting infectious agents quickly and accurately, resulting in a considerable increase in demand for these tests.
Based on End-User, the market is segmented into Hospitals & Clinics, Clinical Laboratories, Pharmaceutical & Biotechnology, Blood Banks, Research & Academic Laboratories and Home Care Settings. The hospitals & clinics segment is estimated to show the highest growth in the forecasted period due to a wide range of services such as diagnostic testing, patient care, and illness treatment. Hospitals and clinics provide primary healthcare to the great majority of the population, allowing for disease detection, diagnosis, and treatment at an early stage. The large patient volume in these settings raises the demand for immunoassay tests, making them an essential component of patient care practices.
Based on Geography, the immunoassay market is classified into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. North American region is estimated to hold the largest share in the immunoassay market. North America, particularly the United States, has a highly developed healthcare system that allows for the rapid adoption and integration of new diagnostic technology, such as immunoassays. The region's significant investment in healthcare and R&D promotes innovation and the development of novel immunoassay techniques and platforms.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.